EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

Identification of TGFB1 and TIMP1 as the biomarkers of clear cell renal cell carcinoma by bioinformatic methods

Xiaoqi Deng, Jinlan Wu, Mengxi He, Yu Luo

MedBA Medicine · 2026-03-15 · 1 (1) · 27-39

DOI: 10.65079//mbam03 ↗

At a glance

Journal article in MedBA Medicine, published online on 2026-03-15. Written by Xiaoqi Deng and 3 co-authors. The full text is freely available (open access, CC BY 4.0).

AstrattDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

Clear cell renal cell carcinoma (ccRCC) is the most common histological subtype of kidney cancer and is associated with high mortality and poor prognosis. This study aimed to identify potential biomarkers and therapeutic candidates for ccRCC through integrated bioinformatic analyses and molecular docking.

Methods

Microarray datasets from the Gene Expression Omnibus (GEO) database (GSE11024, GSE16441, GSE36895) were analyzed to identify differentially expressed genes (DEGs). The identified DEGs were subsequently validated using The Cancer Genome Atlas (TCGA) database. Key genes associated with ccRCC progression were further investigated. Potential therapeutic compounds targeting these genes were screened, and their binding interactions were evaluated through molecular docking.

Results

A total of 608 overlapping DEGs were identified, including 267 upregulated and 341 downregulated genes. Among these, TGFB1 and TIMP1 were identified as key genes closely associated with ccRCC progression. TCGA validation confirmed that TGFB1 and TIMP1 expression levels were significantly correlated with ccRCC occurrence and progression, exhibiting high expression specificity. Molecular docking analyses revealed that Bosentan and Ramipril formed stable hydrogen bonds with TGFB1, while Meclizine and AM-630 showed favorable binding interactions with TIMP1.

Conclusion

TGFB1 and TIMP1 may serve as promising biomarkers and therapeutic targets for ccRCC, providing new insights into its diagnosis and targeted treatment. Keywords: Clear cell renal cell carcinoma, Metastasis, Biomarkers, Active drugs, Molecular docking

Cite

APA

Deng, X., Wu, J., He, M., & Luo, Y. (2026). Identification of TGFB1 and TIMP1 as the biomarkers of clear cell renal cell carcinoma by bioinformatic methods. MedBA Medicine, 1(1), 27-39. https://doi.org/10.65079//mbam03

Vancouver

Deng X, Wu J, He M, Luo Y. Identification of TGFB1 and TIMP1 as the biomarkers of clear cell renal cell carcinoma by bioinformatic methods. MedBA Medicine. 2026;1(1):27-39. doi:10.65079//mbam03

BibTeX
@article{Deng2026,
  author = {Deng, Xiaoqi and Wu, Jinlan and He, Mengxi and Luo, Yu},
  title = {Identification of TGFB1 and TIMP1 as the biomarkers of clear cell renal cell carcinoma by bioinformatic methods},
  journal = {MedBA Medicine},
  year = {2026},
  volume = {1},
  number = {1},
  pages = {27--39},
  doi = {10.65079//mbam03}
}
Start for free →